Press Releases

Press Releases

Samsung Biologics appoints new leadership to oversee quality and regulatory affairs

COMPANY NEWS, Samsung biologics appoints new leadership to oversee quality and regulatory addairs
 

· Distinguished industry leaders with extensive track records in quality assurance and regulatory affairs join Samsung Biologics to support the company’s quality-driven business operation.  

 

Incheon, S. Korea, August 24, 2023 – Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced the appointments of Gail Ward as executive Vice President and Head of the Quality Center, and Sojeong Lee as Vice President and Head of Regulatory Affairs.

 

A seasoned pharmaceutical executive, Ward has almost four decades of extensive quality experience in both large pharmaceutical companies and entrepreneurial biotech companies. Prior to joining Samsung Biologics, Ward served as Head of Quality at ProKidney Corporation, a late clinical-stage biotech company specializing in treatments for chronic kidney disease. Her experience also includes quality assurance leadership roles at Celltrion, and senior positions at Diosynth RTP and Biogen.

 

Samsung Biologics also appointed Sojeong Lee as the Vice President and Head of Regulatory Affairs to oversee and manage the company’s response to and relationship with global regulatory agencies. Prior to this role, Lee served as the Regulatory Affairs Director at GlaxoSmithKline in Korea.


COMPANY NEWS, Samsung biologics appoints new leadership to oversee quality and regulatory addair
 

· Distinguished industry leaders with extensive track records in quality assurance and regulatory affairs join Samsung Biologics to support the company’s quality-driven business operation.  

 

Incheon, S. Korea, August 24, 2023 – Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced the appointments of Gail Ward as executive Vice President and Head of the Quality Center, and Sojeong Lee as Vice President and Head of Regulatory Affairs.

 

A seasoned pharmaceutical executive, Ward has almost four decades of extensive quality experience in both large pharmaceutical companies and entrepreneurial biotech companies. Prior to joining Samsung Biologics, Ward served as Head of Quality at ProKidney Corporation, a late clinical-stage biotech company specializing in treatments for chronic kidney disease. Her experience also includes quality assurance leadership roles at Celltrion, and senior positions at Diosynth RTP and Biogen.

 

Samsung Biologics also appointed Sojeong Lee as the Vice President and Head of Regulatory Affairs to oversee and manage the company’s response to and relationship with global regulatory agencies. Prior to this role, Lee served as the Regulatory Affairs Director at GlaxoSmithKline in Korea.


SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION